ANIX

Business Context and Reporting Period

Company: Anixa Biosciences, Inc. (NASDAQ: ANIX)
Filing Type: Form 10-K (Annual Report)
Period Ended: October 31, 2024
Business Overview: Anixa is a biotechnology company focused on oncology, developing chimeric endocrine receptor-T cell (CAR-T) therapies for ovarian cancer via its subsidiary Certainty Therapeutics, and cancer vaccines targeting breast (TNBC) and ovarian cancers. The company relies on strategic collaborations with The Wistar Institute, H. Lee Moffitt Cancer Center, and The Cleveland Clinic Foundation. It has no commercial product revenue and operates as a pre-revenue clinical-stage entity.

Key Financial Metrics

Note: The filing does not provide specific gross margin or operating margin percentages due to the absence of product revenue.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to $0 in FY2024 from $210,000 in FY2023. The prior year revenue was a one-time, non-recurring payment from a legacy patent licensing agreement with no future obligations.
• Increased Net Loss: Net loss increased by approximately 28% to $12.7 million, driven by higher operating expenses.
• R&D Expense Growth: R&D expenses rose by $1.63 million (34%) to $6.40 million. Increases were primarily due to accelerated development of the CAR-T program ($845k increase) and breast cancer vaccine program ($834k increase), partially offset by a decrease in ovarian cancer vaccine expenses.
• G&A Expense Growth: G&A expenses increased by $1.14 million (18%) to $7.44 million, largely due to higher investor relations costs ($629k) and increased stock-based compensation.
• Cash Position: Total cash and short-term investments decreased by approximately $3.9 million to $19.9 million, reflecting operating cash burn of $7.3 million, partially offset by $2.96 million raised via an at-the-market equity offering.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Liquidity: Management believes existing cash resources ($19.9 million) are sufficient to fund operations for at least the next 12 months as of January 10, 2025.
• Clinical Progress:
  • CAR-T (Ovarian Cancer): Phase 1 dose-escalation trial is ongoing. Two patients in the third dose cohort (10x higher dose) have been treated as of January 2025. The fourth dose cohort is expected to commence shortly after February 2025.
  • Breast Cancer Vaccine: Phase 1 trial data presented in November 2024 showed antigen-specific immune responses across all patient groups. The company anticipates commencing a Phase 2 neo-adjuvant trial in 2025.
  • Ovarian Cancer Vaccine: Pre-clinical work is being supported by the NCI PREVENT program at no material cost to the company.
• Capital Strategy: The company maintains an effective at-the-market equity program with up to $97 million available for sale. Future funding may be required via equity or debt, which could result in dilution.

Risks and Contingencies

• Pre-Revenue Status: The company has never generated revenue from its core biotechnology programs and may never achieve profitability.
• Capital Needs: Significant additional funding will be required to advance clinical trials and commercialize products. Failure to secure funding could force a reduction in operations.
• Clinical Trial Risks: High uncertainty regarding patient enrollment, safety, and efficacy. Most drug candidates fail to reach commercialization.
• Intellectual Property: Reliance on licenses from third parties (Wistar, Cleveland Clinic). Termination of these licenses would severely impact operations.
• Stock Volatility: As a smaller reporting company with a history of losses, the stock price is subject to significant volatility.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $19.9 million cash balance against the projected burn rate for the upcoming Phase 2 breast cancer vaccine trial and continued CAR-T dose escalation.
• Clinical Data: Review the full data presentation from the Society for Immunotherapy of Cancer (SITC) Annual Meeting regarding the breast cancer vaccine immune responses.
• Dilution Risk: Assess the impact of the active at-the-market offering program and outstanding stock options (13.5 million shares) on shareholder ownership.
• License Dependencies: Confirm the status and milestone obligations of the exclusive licenses with The Wistar Institute and The Cleveland Clinic Foundation.
• Noncontrolling Interest: Note the $1.11 million noncontrolling interest deficit attributable to The Wistar Institute's 4.4% stake in the Certainty Therapeutics subsidiary.